Back to Authors

Schwab, Gisela

Mayo Clinic

Exelixis (United States)

Citations 3

Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Basch, Ethan , Becker, Claus, Rogak, Lauren J. , Spears, Patricia A. , Smith, Mary Lou , Gounder, Mrinal M. , Mahoney, Michelle R., Mendoza, Tito R. , Cleeland, Charles S. , Sloan, Jeff A. , Schwab, Gisela, Atkinson, Thomas M. , Thanarajasingam, Gita , Dueck, Amylou C. , Bennett, Antonia V , Bertagnolli, Monica M , Dueck, A. C. , Mendoza, Tito , Basch, Ethan , Schrag, Deborah , Reeve, Bryce B. , Schwartz, Gary K. , Bruner, Deborah Watkins , Bertagnolli, Monica M.

Clinical Trials | December 1, 2020 | Volume: 18 | Issue: 1 | Pages: 104-114

10.1177/1740774520975120 Get It

Background: The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events is an item library designed for eliciting patient-reported adverse events in oncology. For each adverse event, up to three individual items are scored for frequency, severity, and interference with daily activities. To align the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events with other standardized tools for adverse event assessment including the Common Terminology Criteria for Adverse Events, an algorithm for mapping individual items for any given adverse event to a single composite numerical grade was developed and tested. Methods: A five-step process was used: (1) All 179 possible Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events score combinations were presented to 20 clinical investigators to subjectively map combinations to single numerical grades ranging from 0 to 3. (2) Combinations with <75% agreement were presented to investigator committees at a National Clinical Trials Network cooperative group meeting to gain majority consensus via anonymous voting. (3) The resulting algorithm was refined via graphical and tabular approaches to assure directional consistency. (4) Validity, reliability, and sensitivity were assessed in a national study dataset. (5) Accuracy for delineating adverse events between study arms was measured in two Phase III clinical trials (NCT02066181 and NCT01522443). Results: In Step 1, 12/179 score combinations had <75% initial agreement. In Step 2, majority consensus was reached for all combinations. In Step 3, five grades were adjusted to assure directional consistency. In Steps 4 and 5, composite grades performed well and comparably to individual item scores on validity, reliability, sensitivity, and between-arm delineation. Conclusion: A composite grading algorithm has been developed and yields single numerical grades for adverse events assessed via the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, and can be useful in analyses and reporting.
Composite grading algorithm for National Cancer Institute’s PRO-CTCAE.
Becker, Claus, Rogak, Lauren J. , Spears, Patricia A. , Smith, Mary Lou , Gounder, Mrinal M. , Mahoney, Michelle R., Cleeland, Charles S. , Sloan, Jeff A. , Schwab, Gisela, Atkinson, Thomas M. , Thanarajasingam, Gita , Basch, Ethan , Dueck, Amylou C. , Schrag, Deborah , Reeve, Bryce B. , Schwartz, Gary K. , Bennett, Antonia V , Mendoza, Tito R. , Bruner, Deborah Watkins , Bertagnolli, Monica M. , Basch, Ethan

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 7018-7018

10.1200/jco.2020.38.15_suppl.7018 Get It

7018 Background: Standard reporting of symptomatic adverse events (AEs) in oncology relies on clinicians to rate patient (pt) experience using CTCAE; each symptom is represented by a single graded item. To capture direct pt experience, NCI developed PRO-CTCAE to supplement CTCAE. In PRO-CTCAE, the pt answers up to 3 questions per AE about a symptom’s frequency, severity and interference with daily activities. To align PRO-CTCAE with CTCAE, we developed an algorithm for mapping sets of questions for an AE to a single composite numerical grade. Methods: We used a 5-step process. (1) All 187 possible PRO-CTCAE score permutations were presented to clinical investigators to subjectively map permutations to single numerical grades (range 0-3). (2) Permutations with < 75% agreement were presented to investigator committees at a National Clinical Trials Network meeting to gain majority consensus via anonymous voting. (3) The resulting algorithm was refined via graphical and tabular approaches to assure directional consistency. (4) Validity, reliability and sensitivity were assessed in a national study dataset. (5) Accuracy for delineating AEs between study arms was measured in 2 phase III clinical trials (Alliance for Clinical Trials in Oncology A091105 and Exelixis COMET-2). Results: (1) 12/187 score permutations had < 75% initial agreement. (2) Majority consensus was reached for all permutations. (3) 5 mappings were adjusted to assure directional consistency. (4) Composite grades for 46/59 (78%) AEs were higher in pts with ECOG performance status 2-4 vs 0-1 (median effect size 0.23 [range -0.49-0.73]; 32/59 effect size ≥0.2; 25/59 p< 0.05), similar to when conducting analysis on individual unmapped items. The test-retest reliability for 24 selected composite grades ranged from 0.57-0.96 (median intraclass correlation coefficient [ICC] 0.77) with 18/24 (75%) grades having ICC ≥0.7. Median (range) standardized response means in pts reporting worsening, no change, and improvement were 0.20 (0.03-0.34), -0.06 (-0.20-0.03) and -0.12 (-0.32-0.06). (5) Pattern, directionality and statistical significance of between-arm differences in both trials were preserved with composite grades as compared to individual unmapped items. Conclusions: A composite grading algorithm for PRO-CTCAE was rigorously developed and validated. PRO-CTCAE composite grades may be useful in analyses to provide a single metric for each pt-reported AE for trial and real-world reporting. Support: UG1CA189823; U01CA233046; HHSN261200800043C; Bayer (A091105); https://acknowledgments.alliancefound.org .
Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial
Dueck, Amylou C. , Scher, Howard I. , Mazza, Gina L. , Thanarajasingam, Gita , Schwab, Gisela, Weitzman, Aaron, Rogak, Lauren J. , Basch, Ethan , Dueck, A. C. , Mazza, Gina L , Bennett, Antonia V , Basch, Ethan

JAMA Oncology | September 26, 2019 | Volume: 6 | Issue: 2 | Pages: e193332

10.1001/jamaoncol.2019.3332 Get It